BridgeBio Pharma Inc (NAS:BBIO)
$ 28.71 -0.56 (-1.91%) Market Cap: 5.37 Bil Enterprise Value: 6.69 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 52/100

BridgeBio Pharma Inc at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 05:00PM GMT
Release Date Price: $13.83 (+0.51%)
Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thanks so much. Really appreciate the time and the opportunity to present here, and thanks for everyone for coming.

There's a lot going on right now at BridgeBio. We have 3 Phase IIIs already commenced or about to commence in ADH1, achondroplasia, and LGMD2i, and obviously, an important Phase II data set reading out later this year in congenital adrenal hyperplasia. But I wanted to spend the entirety of my time today talking about a key program in ATTR-Cardiomyopathy, one of our big catalysts that's upcoming this year, which is the final readout from our Phase III ATTRibute trial.

And I want to spend some time on -- move this forward to Slide 2. The key questions highlighted on this second slide. First of all, what are the clinical expectations from this trial? And how might we compare the clinical data that we produce from a tribute to already available therapies and specifically, what does superiority look like?

I want to then tie those clinical expectations to commercial expectations, where we've

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot